BIOPSYCHOSOCIAL APPROACHES TO OBSESSIVE-COMPULSIVE, BODY IMAGE AND EATING DISORDERS
Dr Nicola Acevedo, Neuroscientist and Research Fellow
Swinburne University of Technology, Melbourne, Australia
& Consultant, Neurotech Insights, Melbourne, Australia &
Director, BioAutism, Melbourne, Australia & Vice-President
Australasian Brain Stimulation Society
RESEARCHER PROFILE
Filmed in Melbourne, Australia | December 2025
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.
Nicola completed her PhD on deep brain stimulation for treatment-refractory OCD- described as a “tour de force”- producing eight first-author peer-reviewed publications and multiple international collaborations and papers. She now leads research in psilocybin-assisted psychotherapy for OCD, body dysmorphic disorder, and anorexia nervosa. Her work has been presented at leading international forums including Oxford and Harvard University, and the Royal Australian and New Zealand College of Psychiatrists Congress.
Alongside her research, Nicola holds leadership positions across brain stimulation, OCD, and ethics committees, serves on a peer review board, and is Director of the charity BioAutism Ltd. She also provides mentorship and supervision, with a commitment to supporting junior researchers. Her contributions have been recognised with the Early Career Researcher (ECR) Excellence Award from Biological Psychiatry Australia. As an ECR, Nicola is driven by the potential to innovate and make an impact in national mental health services.
Source: Supplied
https://orcid.org/0000-0003-3059-3620
-
Infections and other lung diseases using models of human lung tissue grown from stem cells
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
-
Therapy to prevent hepatocellular carcinoma in people with liver cirrhosis
Professor John Olynyk is a Gastroenterologist & Hepatologist with over 30 years’ experience, primarily at The Fiona Stanley & Fremantle Hospital Group. He planned the Gastroenterology and Hepatology Service for the Fiona Stanley Hospital and was Head Department from 2010 until 2020.
Professor John Olynyk was appointed as Associate Dean and Head of the Medical Discipline at Curtin University in 2023 until 2025 and is now Associate Director, Clinical Engagement, Curtin Medical Research Institute, Curtin University.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
